Baycol (Cerivastatin (Removed from Market 8/2001)) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 25, 2012

Baycol

Peripheral Vascular Disease »

What is peripheral vascular disease?

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. While there are many causes of peripheral vascular disease, doctors commonly use the term peripheral vascular disease to refer to peripheral artery disease (peripheral arterial disease, PAD), a condition that develops when the arteries that supply blood to the internal organs, arms, and legs become completely or partially blocked as a result of atherosclerosis.

What is atherosclerosis?

Atherosclerosis is a gradual process whereby hard cholesterol substances (plaques) are deposited in the walls of the arteries. Cholesterol plaques cause hardening of the artery walls and narrowing of the inner channel (lumen) of the artery. The atherosclerosis process begins early in life (as early as teens in some people). When atherosclerosis is mild an...

Read the Peripheral Vascular Disease article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Baycol

Adult Skin Problems Slideshow Pictures

How Smoking Affects Your Looks Slideshow Pictures

Weight Gain Shockers Slideshow

font size

Please Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

OVERDOSE

No specific recommendations concerning the treatment of an overdosage can be made. Should an overdose occur, it should be treated symptomatically and supportive measures should be undertaken as required.

Dialysis of cerivastatin sodium is not expected to significantly enhance clearance since the drug is extensively ( > 99%) bound to plasma proteins.

CONTRAINDICATIONS

Active liver disease or unexplained persistent elevations of serum transaminases (see WARNINGS). Concurrent treatment with gemfibrozil due to a risk for rhabdomyolysis (see WARNINGS: Skeletal Muscle).

Pregnancy and lactation: Atherosclerosis is a chronic process, and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, HMG-CoA reductase inhibitors are contraindicated during pregnancy and in nursing mothers. Cerivastatin sodium should be administered to women of child-bearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking this drug, cerivastatin sodium should be discontinued and the patient should be apprised of the potential hazard to the fetus. Hypersensitivity to any component of this medication.